Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer by Johanna N. Spaans & Glenwood D. Goss
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINI REVIEW ARTICLE
published: 23 July 2014
doi: 10.3389/fonc.2014.00190
Drug resistance to molecular targeted therapy and its
consequences for treatment decisions in non-small-cell
lung cancer
Johanna N. Spaans1 and Glenwood D. Goss1,2,3*
1 Ottawa Hospital Research Institute, Ottawa, ON, Canada
2 Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
3 Department of Medicine, University of Ottawa, Ottawa, ON, Canada
Edited by:
Vera Hirsh, McGill University Health
Centre, Canada
Reviewed by:
Gregory Masters, Medical Oncology
Hematology Consultants, PA, USA
Janaki Deepak, University of
Maryland School of Medicine, USA
*Correspondence:
Glenwood D. Goss, 501 Smyth Road,
Ottawa, ON K1H 8L6, Canada
e-mail: ggoss@toh.on.ca
Our ability to detect and directly target the oncogenic alterations responsible for tumor
proliferation has contributed significantly to the management of lung cancer in the last
decade. The therapeutic efficacy of molecularly targeted therapy is, however, mainly lim-
ited to patients harboring certain genetic mutations and is generally short-lived. Herein, we
review primary and secondary drug resistance using the most well-studied of the molecu-
larly targeted agents, the tyrosine kinase inhibitors targeting the epidermal growth factor
(EGF) receptor, and the anaplastic lymphoma kinase (ALK) rearrangement, the current limi-
tations of targeted therapies and their consequences on the management of patients with
lung cancer.
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The treatment of advanced non-small-cell lung cancer (NSCLC)
had reached a therapeutic plateau prior to the introduction of
molecularly targeted agents (MTAs), with a median survival of
8–12 months (1, 2). With an improved understanding of the
molecular biology of lung cancer, enabled by advances in high-
throughput technology, have come molecular therapies that target
specific receptors and oncogenic pathways responsible for tumor
growth and proliferation. Despite the demonstrated superiority of
these MTAs over standard chemotherapy in subgroups of patients
(3, 4), their therapeutic efficacy is limited to patients harboring the
targeted genetic aberration and is generally short-lived. Any future
advances in the survival of patients with advanced NSCLC will
hinge on our ability to expand on the percentage of patients eligible
and responsive to targeted therapy and our capacity to mitigate the
mechanisms of acquired resistance that prevent long-term disease
control.
As the most well-studied of the MTAs, tyrosine kinase inhibitors
in NSCLC targeting the epidermal growth factor (EGF) receptor
(erlotonib, gefitinib, and afatinib) and the anaplastic lymphoma
kinase (ALK) rearrangement (crizotinib) provide a useful frame-
work in which to understand the current limitations of molecu-
larly targeted therapy and their consequences in the management
of patients with NSCLC.
PRIMARY RESISTANCE TO EGFR INHIBITORS
The EGFR pathway is known to be active in NSCLC (5) and protein
overexpression is known to be associated with poorer prognosis
(6). Early on in the clinical development of EGFR-tyrosine kinase
inhibitors (EGFR-TKIs), which targeted this pathway, it was real-
ized that patients whose tumor harbored an activating mutation
in the EGFR gene at exons 19 and 21 had more dramatic responses
and better clinical outcomes than their EGFR wild-type (W/T)
counterparts (7, 8). This has resulted in some countries limiting
regulatory approval in the first-line setting to patients whose
tumors harbor these sensitizing mutations (9). Although com-
mon among lung cancer patients of Asian descent (10), sensitizing
EGFR mutations are relatively uncommon in North American
and European NSCLC populations with a prevalence of ~15%
in patients with advanced non-squamous histology (11). Further,
despite their heightened sensitivity to EGFR-TKIs, as many as
one third of NSCLC patients with tumors with sensitizing EGFR
mutations do not respond to targeted therapy (12, 13).
The mechanisms of primary resistance to EGFR-TKIs are best
considered in terms of patients with tumors with (EGFR mutant)
and without (EGFR W/T) sensitizing mutations. In the latter case,
patients may not respond to EGFR-TKIs because their tumors are
being driven by other oncogenic pathways that are not sensitive
to EGFR inhibition. Indeed, different oncogenic alterations have
been identified in up to half of patients with EGFR W/T disease
(14). Importantly, the successful targeting of one such alteration,
namely the ALK gene rearrangement with crizotinib (15) demon-
strates the feasibility of addressing this form of primary resistance
in the EGFR W/T population. Therapies targeting other mutations
that commonly occur among EGFR W/T patients such as c-ros
oncogene 1 (ROS1), ret proto-oncogene (RET), v-raf murine sar-
coma viral oncogene homolog B (BRAF), and the human EGF 2
(HER2) are currently under development.
In addition, primary resistance in the EGFR W/T population
may be the result of activation of alternate parallel signaling path-
ways, which can overcome EGFR blockade, that are independent of
a pathway-specific activating mutation. Activation of the insulin-
like growth factor receptor (IGFR) pathway (16) is one such
potential mechanisms of primary resistance. Blockade of these
alternate pathways to enhance EGFR TKI efficacy is a strategy
that is being investigated, but to date has yielded mixed results
(17–19). Lack of response to EGFR-TKIs among patients with
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W/T tumors may also be due to incomplete binding of the drug
to the EGF receptor or because of insufficient drug concentration
necessary for effective pathway blockade (20). Further, as only one
of four receptor tyrosine kinases in the ERbB family (21, 22), the
isolated targeting of the EGF/Erb1 receptor may not prevent auto-
phosphorylation and downstream pathway activation by the other
receptors (i.e., Erb2, Erb3, Erb4). Newer second-generation irre-
versible pan-HER tyrosine kinase inhibitors such as dacomitinib
and afatinib that target multiple receptors are being evaluated in
both EGFR W/T and EGFR-mutant populations as a strategy to
enhance and prolong treatment response (23, 24).
In patients with tumors with EGFR sensitizing mutations a
number of factors have been identified in the primary resistance
setting, which may modulate or blunt the therapeutic efficacy of
EGFR-TKIs. While most oncogenic driver mutations are mutually
exclusive in context of lung cancer, the co-existence of EGFR muta-
tions with other oncogenic alterations, including class A phospho-
inositide 3-kinase (PI3KCA), have been reported (25). Activation
of compensatory signaling pathways by these other mutations
may afford continued disease progression and negate or circum-
vent clinical benefit derived from EGFR TKIs in patients whose
tumors harbor EGFR mutations. The dual targeting of co-existing
mutations with combination therapy in EGFR-mutant disease is
currently under investigation (clinical trials.gov: NCT01570296).
In a similar fashion, exogenous factors, including MED12-
mediated transforming growth factor beta (TGF-β) activation
(26) and hepatocyte growth factor (HGF) ligand overexpres-
sion (27), may enable the activation of alternate signaling path-
ways in tumors that may override the pathways inhibited by
the EGFR-TKIs. The inhibition of these compensatory pathways
in tumors with EGFR sensitizing mutations is a hot topic in
clinical research with the testing of a number of combination
therapies that include agents to overcome TGF-β and HGF-
mediated resistance [e.g., heat shock protein (Hsp) 90 inhibitors]
in both the primary (clinicaltrials.gov: NCT01714037) and resis-
tance setting (clinicaltrials.gov: NCT01259089, NCT01288430,
NCT01851096).
Finally, exogenous apoptotic factors have been identified that
may modulate the impact of EGFR TKIs in patients with tumors
with sensitizing EGFR mutations and may explain their variable
treatment response. Increasing evidence suggests that expres-
sion levels of proapototic BH-3 only molecule (BIM) can influ-
ence treatment-induced apoptosis (28, 29) and further that pre-
treatment BIM expression may play a role in treatment response
to many kinase inhibitors across many disease sites (30, 31). While
in lung cancer, it has been shown that low pre-treatment BIM lev-
els are associated with shorter time to progression (29), available
pro-apoptotic assays are not currently being used in clinical prac-
tice to predict treatment response. Targeted therapies with B-cell
lymphoma 2 (blc2) inhibitors that enhance apoptosis, however,
are currently being evaluated in combination with EGFR-TKIs
as a strategy to enhance treatment response (clinicaltrials.gov:
NCT00988169).
Despite early and dramatic treatment responses in up to two
thirds of patients with EGFR sensitizing mutations, most patients
will eventually progress while on therapy within a year of treat-
ment initiation (12). Beyond the level of pre-treatment apoptotic
factors, such as BIM discussed previously, a number of other
factors have been suggested to influence the development of
clonal and sub-clonal EGFR-resistant cell populations. Specifi-
cally, both factors affecting the drug metabolism and character-
istics of the treatment schedules may impact the development of
acquired resistance in previously responsive patients (32). While
the higher metabolic clearance of EGFR-TKIs among smokers
and fast metabolizers has long been recognized as a negative
predictor for time to progression (33), only recently have the
pharmacokinetics of different dosing schedules been considered
for their potential influence on the evolution of drug resistance
to EGFR TKIs. Specifically, based on evolutionary modeling and
clinical data, it has been proposed that pulsed high dose with
continuous low dose EGFR-TKI treatment helps to maintain sen-
sitive cell populations and may extend the therapeutic benefit
of EGFR-TKI therapy beyond progression (34). While standard
once daily dosing continues to be used in the clinic for approved
MTAs, research is on-going to define characteristics of the treat-
ment regimen that may delay disease progression and optimize
therapeutic outcomes with EGFR-TKI therapy (clinicaltrials.gov:
NCT01967095).
Although criteria for acquired resistance have now been devel-
oped (35), resistant disease is best considered along an evolu-
tionary continuum, where resistant clones eventually overrun
EGFR-sensitive cells, leading to the clinical characteristics of dis-
ease progression. The existence of EGFR-sensitive cells in tumors
that progress is supported by reports of clinical response in patients
re-challenged with EGFR-TKIs (36) and also by reports of disease
flare in up to 15% of patients who are taken off EGFR-TKI therapy
at disease progression (37).
SECONDARY EGFR-TKI RESISTANCE
Genetic adaptations and altered network signaling pathways
invariably lead to drug resistance in patients whose tumors har-
bor EGFR sensitizing mutations who initially respond to EGFR-
targeted therapy (acquired resistance). Molecular profiling of
tumors with acquired resistance to EGFR-TKIs has identified a
number of resistance mechanisms and dominant acquired resis-
tance phenotypes, which may be useful in guiding future treat-
ment. The most common mechanism of acquired resistance to
EGFR-TKI is the development of a second mutation of the EGFR
that is resistant to therapy. While a number of secondary mutations
have been identified (38), the most common “gatekeeper” muta-
tion is that of the T790M, which occurs in 50–60% of patients with
acquired resistance to EGFR-TKIs (39). This secondary mutation
is believed to exert its effect by enhancing ATP kinase affin-
ity, thereby decreasing sensitivity to the ATP-competitive EGFR
TKIs (40). Importantly, the development of secondary resistance
mutations in the EGFR kinase domain has implications in the
re-challenging of patients with previously sensitive disease and
has fueled research in the development of second and third gen-
eration inhibitors (41–45). Despite encouraging phase II data
of one such second-generation inhibitor (dacomitinib) in pre-
viously treated patients (41, 42), emerging phase III data suggests
that there is no overall survival benefit associated with its use
in previously treated EGFR W/T patients or those with acquired
EGFR-TKI resistance (23). Similarly, while interim analysis of
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another second-generation irreversible ErbB family blocker (Afa-
tinib) in patients with acquired resistance to EGFR-TKIs suggested
improved progression-free survival (PFS) (43), the lack to an over-
all survival benefit observed in this phase 2b/3 randomized trial
(24) does not support the strategy of extended EGFR blockade in
the EGFR-resistant population.
Most recently, the finding of a T790M mutation in tumors at
the time of initial diagnosis (44, 45) has implicated the mutation
in primary EGFR-TKI resistance, suggesting that up-front treat-
ment with second/third generation EGFR-TKIs may confer added
benefit over their use in the second-line setting in patients with
T790M-mediated acquired resistance. Indeed, preliminary clini-
cal reports of second-generation EGFR inhibitors in the first-line
treatment setting support their up-front use in patients whose
tumors harbor EGFR mutations (46, 47).
An alternate mechanism of secondary resistance is the activa-
tion of other signaling pathways by adaptive de novo alterations
that develop outside the EGFR kinase domain in response to treat-
ment. A number of these alterations have been identified; the most
well-studied being MET amplification, which occurs in 10–20%
of patients with EGFR-TKI resistant disease (48). Other less com-
mon mutations include HER2 amplification (49, 50), activation of
PIK3Ca (51) and BRAF (52), and loss of phosphatase and tensin
homolog (PTEN) function (53).
Crosstalk between key signaling pathways may also play a role
in the development of acquired resistance to EGFR inhibitors.
Specifically, the activity of the angiogenic VEGF pathway has been
suggested to play a role in resistance to EGFR-TKIs (54), which is
not surprisingly given the common downstream effectors shared
by these parallel pathways (55). Although preclinical data across
different tumor types (56, 57) and early phase lung cancer clinical
trials (58, 59) pointed to the potential utility of dual inhibition of
VEGF and EGFR, phase III data of the dual inhibitor vandetanib
suggest that this is not a promising approach to overcome acquired
resistance to EGFR-TKIs in advanced NSCLC (60).
Finally, a less common but well documented mechanism of
acquired resistance to EGFR-TKIs is histological transforma-
tion from NSCLC to SCLC or epithelial–mesenchymal transi-
tion (EMT), which has been reported in up to 3% of EGFR-
TKI resistant patients (61). Increasing evidence suggest that
these transformations are linked to the activation of the AXL
kinase, the inhibition of which may restore EGFR-TKI sensitiv-
ity in previously resistant cells (62). Collectively, these mech-
anisms clearly demonstrate the multitude of adaptive strate-
gies developed by the tumor to ensure its continued growth
and underscores the complexity of treating EGFR-TKI-resistance
disease.
While the above resistant disease phenotypes are useful in
the classification of acquired resistance, these adaptive mecha-
nisms may not be mutually exclusive. Indeed, it has recently been
proposed that T790M mutations and MET amplifications are
complementary and may co-exist in the development of drug resis-
tance (63). In addition, oncogenic driver mutations may be tumor
specific, as different driver mutations from different tumor sites
within the same individual have been identified in patients with
EGFR-TKI resistant disease (39), further illustrating the challenges
in managing patients with acquired resistance.
PRIMARY RESISTANCE TO ALK INHIBITORS
Between 1 and 3% of patients with advanced NSCLC have tumors
that harbor sensitizing chromosomal rearrangements of the ALK
gene (64–66). The ALK inhibitor crizotinib has recently been
approved for the treatment of patients with ALK-positive tumors,
however, as with EGFR-TKIs not all patients respond to ther-
apy. Specifically, while phase III studies have shown that crizo-
tinib improves PFS compared to chemotherapy in previously
treated NSCLC patients with ALK-positive disease (HR= 0.49
95% CI: 0.37–0.64,p< 0.001), only 65% of patients were shown to
respond to therapy (67). While primary resistance among patients
with ALK-positive tumors is less well-understood, the occur-
rence of drug-resistant ALK mutations and compensatory mech-
anisms have been advanced as potential mechanisms of primary
resistance (68).
In summary, less than 20% of patients have tumors with an
EGFR or ALK mutation at the time of diagnosis, and of these,
only 60–70% of patients respond to currently available MTAs.
Therefore, we are mandated to address the approximately 80%
of patients whose tumors are de novo resistant to EGFR and
ALK inhibition, a percentage of whom are resistant due to other
oncogenic driver mutations such as Kirsten rat sarcoma viral onco-
gene homolog (KRAS), BRAF, and RET, among others. Many
investigations targeting these mutations are on-going.
SECONDARY RESISTANCE TO ALK INHIBITORS
While secondary mutations in the ALK domain have been iden-
tified in approximately one-third of the patients with acquired
resistance to ALK inhibitors (69), unlike acquired resistance to
EGFR-TKIs, there does not appear to be a dominant secondary
mutation. Further complicating the management of such patients,
multiple mutations within the same individual have also been
reported in patients with acquired resistance (70). Of note, second-
generation ALK inhibitors have, however, recently shown high
response rates (48% confirmed responses) in patients previously
treated with crizotinib, in tumors with and without secondary
mutations in ALK (71). These results support the importance of
ALK in crizotinib-resistant disease and the continued effort in
targeting the ALK domain.
TREATMENT IMPLICATIONS
Since the publication of the initial reports over a decade ago, we
now have a much better understanding of which patients stand to
benefit most from targeted therapies with EGFR and ALK tyro-
sine kinase inhibitors and the intrinsic and adaptive mechanisms
that limit treatment response and inevitably lead to acquired drug
resistance. Despite these treatment advances, there are currently
a limited number of therapeutic options available to patients not
harboring sensitizing EGFR mutations or rearrangement of the
ALK gene. Further, the mechanisms of acquired resistance among
those who initially respond to treatment remain uncharacterized
in almost 40% of patients with acquired resistance (72). That said,
many agents targeting other oncogenic mutations are in phase III
development, and in the near future will expand the armamentar-
ium of targeted therapies available in the treatment of advanced
NSCLC. The following strategies are proposed in the current and
future management of patients with NSCLC.
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All patients presenting with advanced NSCLC should be
screened for all known oncogenic driver mutations with treatment
assigned accordingly based on available molecularly targeted ther-
apies. With the approval of second line and third line (T790M
specific) EGFR-TKIs, it may also be useful to screen up-front
for T790M mutations and preferentially treat patients harboring
these mutations with these second and third generation therapies,
given the shorter PFS that patients harboring this mutation expe-
rience with first-line reversible EGFR-TKIs (44). In addition, for
patients harboring sensitizing EGFR mutations, the assessment
of pre-treatment BIM expression may be a useful approach to
help to optimize EGFR-TKI treatment outcomes, with the addi-
tion of anti-apoptotic inhibitors such as Blc2 to the treatment
regimen.
While alternate dosing schedules, such as pulsed high dose with
continuous low dose may be shown to delay time to disease pro-
gression, current treatment regimens of approved targeted agents
are limited to once daily dosing. EGFR-TKI treatment should
ideally be continued in the case of disease progression until the
initiation of second-line therapy, given the potential for disease
flare (37) and data that suggest that patients may benefit from
continued treatment beyond progression (73, 74). As it has been
shown that isolated sites of disease progression may be success-
fully treated while continuing on EGFR-TKIs (75), the decision
to discontinue EGFR-TKI therapy at disease progression should
be considered in the context of available therapeutic alternatives
and the potential benefit of continued EGFR-TKI therapy. For
example, treatment with afatinib in addition to chemotherapy
has recently been shown to delay progression over chemother-
apy alone (5.6 vs. 2.8 months) in patients who had progressed on
afatinib (76).
The optimal treatment of patients with tumors that harbor
EGFR mutations and ALK gene rearrangement who develop
acquired resistance to EGFR and ALK tyrosine kinase inhibitors
has yet to be defined. While most patients are managed with
chemotherapy, the evidence to support this therapeutic approach
is limited and the documented response rate with chemotherapy
in patients with EGFR-resistance disease is l0–20% (77). As more
targeted therapies become available, a more informed approach to
the treatment of acquired disease to targeted therapies may emerge
through rebiopsy at the time of disease progression and tailoring
of subsequent mechanism-based therapies.
Lung cancer is a heterogenous disease and resistance mecha-
nisms to targeted molecular therapy are many. Given the multitude
of signaling pathways and the evolving characteristics of resis-
tant disease, an up-front combination therapy that simultaneously
inhibits multiple resistance pathways is likely to yield better clini-
cal outcomes. Personalized targeted therapy at the time of disease
recurrence may further improve survival. Importantly, an aggres-
sive front-line strategy and a tailored management approach in
the case of resistant disease has been successfully employed in the
management of other diseases, including HIV (78), which has now
come to be considered a chronic disease. Whether advanced lung
cancer may someday have a similar clinical outcome remains to
be seen. To achieve this, attention must be directed at reducing
the toxicity of combination therapies and greater efforts made to
define the molecular basis of acquired resistance.
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